Skip to main content
. 2022 Apr 18;37(16):e128. doi: 10.3346/jkms.2022.37.e128

Table 4. Adverse drug reactions to first-line anti-TB drugs according to age group.

Adverse drug reactions Younger, < 60 yr Older, ≥ 60 yr Missing values Total
Nausea 1,240 (47.5) 1,336 (51.2) 35 (1.3) 2,611
Hepatic enzyme abnormalitya 1,512 (59.7) 971 (38.4) 48 (1.9) 2,531
Rashb 1,138 (54.5) 889 (42.6) 62 (3.0) 2,089
Pruritis 744 (46.0) 851 (52.6) 22 (1.4) 1,617
Vomiting 650 (41.0) 925 (58.3) 12 (0.8) 1,587
Urticaria 417 (56.4) 314 (42.4) 9 (1.2) 740
Anorexia 159 (23.0) 522 (75.4) 11 (1.6) 692
Dyspepsia 250 (40.1) 368 (59.1) 5 (0.8) 623
Dizziness 292 (49.7) 287 (48.9) 8 (1.4) 587
Arthralgia 318 (57.5) 230 (41.6) 5 (0.9) 553
Diarrhea 202 (42.5) 270 (56.8) 3 (0.6) 475
Headache 290 (63.3) 167 (36.5) 1 (0.2) 458
Fever 231 (59.5) 150 (38.7) 7 (1.8) 388
Hyperuricemia 224 (65.3) 115 (33.5) 4 (1.2) 343
Myalgia 134 (59.8) 84 (37.5) 6 (2.7) 224
Abdominal pain 115 (54.0) 97 (45.5) 1 (0.5) 213
Malaise 56 (34.8) 105 (65.2) 0 (0) 161
Eosinophilia 44 (32.4) 90 (67.6) 0 (0) 136
Fatigue 85 (68.0) 40 (32.0) 0 (0) 125
Leucopenia 77 (74.8) 26 (25.2) 0 (0) 103
Dyspnea 40 (43.0) 53 (57.0) 0 (0) 93
Thrombocytopenia 13 (15.9) 68 (83.0) 1 (1.2) 82
Vision abnormality 47 (60.3) 25 (32.1) 6 (7.7) 78
Tremor 31 (41.3) 44 (58.7) 0 (0.0) 75
Cachexia 21 (29.6) 40 (56.3) 10 (14.0) 71
Constipation 15 (23.8) 47 (74.6) 1 (1.6) 63
Weight decrease 16 (29.6) 38 (70.4) 0 (30.0) 54

Data are shown as numbers (row %).

aHepatic enzyme abnormality includes hepatic enzyme increased, hepatic function abnormal, SGOT increased, SGPT increased ‘jaundice, hepatitis, gamma-GT increased, bilirubinemia, hepatocellular damage, and cholecystitis’; bRash includes ‘rash, rash maculopapular and rash erythematous’.